Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (NASDAQ: VERU) is a late clinical stage biopharmaceutical company whose news flow is closely tied to the development of its two lead small molecule drug candidates, enobosarm and sabizabulin. Company press releases emphasize cardiometabolic and inflammatory diseases, with a particular focus on obesity, chronic weight management, and inflammation in atherosclerotic cardiovascular disease.
Much of Veru’s recent news has centered on enobosarm, a selective androgen receptor modulator (SARM) being developed to make weight reduction by GLP-1 receptor agonist (GLP-1 RA) drugs more tissue selective for fat loss while preserving lean mass and physical function. Updates include topline efficacy and safety data from the Phase 2b QUALITY study and its Maintenance Extension, which evaluated enobosarm in older patients receiving semaglutide for weight reduction. The company has reported that enobosarm plus semaglutide preserved lean mass, increased fat loss, and reduced declines in stair climb power compared to placebo plus semaglutide, as well as reduced weight and fat regain after semaglutide discontinuation.
Investors following VERU news will also see announcements about regulatory interactions and trial design. Veru has disclosed a successful FDA meeting that, according to the company, provided regulatory clarity for enobosarm as a muscle preservation drug in combination with GLP-1 RA therapy for obesity, including guidance that incremental weight loss can serve as an acceptable primary endpoint and confirmation of the 3 mg dose for future development. News releases describe the planned Phase 2b PLATEAU study, designed to evaluate enobosarm 3 mg in patients with obesity initiating GLP-1 RA treatment, with endpoints focused on total body weight, body composition, and physical function.
Additional VERU headlines cover capital markets activity and corporate actions, such as an underwritten public offering to fund enobosarm development, a 1-for-10 reverse stock split, and Nasdaq notifications regarding minimum bid price compliance. Conference presentations at scientific meetings, collaborations on a modified release enobosarm formulation using Laxxon Medical’s SPID-Technology, and periodic financial results also feature prominently in the company’s news stream.
For investors and observers, the Veru news page provides a consolidated view of clinical trial milestones, FDA-related updates, financing transactions, and scientific presentations that shape the outlook for VERU’s cardiometabolic and inflammatory disease programs.
Veru, a late clinical-stage biopharmaceutical company listed on NASDAQ under the symbol VERU, reminds shareholders to vote ahead of its 2024 Annual Meeting of Shareholders. The meeting is set for June 18, 2024, at 9:00 AM ET. Shareholders should submit their votes before the proxy voting deadline, which is also on June 18, 2024, at 9:00 AM ET. Voting can be done online or via telephone based on instructions in the Form of Proxy or Voting Instruction Form. Detailed materials are available on the company’s website.
Veru, a clinical stage biopharmaceutical company (NASDAQ: VERU), will present at the American Diabetes Association's 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida.
The company will showcase two presentations on June 22, 2024:
1. A pooled safety analysis of Enobosarm from Phase 2 and Phase 3 placebo-controlled clinical trials.
2. A meta-analysis of body composition from three randomized clinical trials, highlighting Enobosarm’s ability to preserve muscle while reducing fat.
Both presentations are scheduled from 12:30 PM to 01:30 PM EDT at the West Concourse A4-B2.
Veru (NASDAQ: VERU), a biopharmaceutical company, announced that its CEO, Mitchell Steiner, M.D., will present at the Jefferies Global Healthcare Conference on June 5, 2024, from 11:00 am to 11:25 am ET. The presentation will focus on the Phase 2b clinical program of enobosarm. Enobosarm aims to augment fat loss and prevent muscle loss when combined with GLP-1 drugs for weight loss. A live webcast of the presentation will be available on Veru's website, with an archived version accessible post-event.
Veru (NASDAQ: VERU) has announced the appointment of Dr. Steven B. Heymsfield as the Principal Investigator for its Phase 2b clinical trial of enobosarm, aimed at preserving muscle while enhancing fat loss in patients using GLP-1 RAs for weight loss.
Dr. Heymsfield is a renowned expert in body composition and obesity, with extensive experience in clinical research and over 600 peer-reviewed publications. The trial seeks to address the issue of muscle loss in weight loss treatments. Veru anticipates enrolling the trial quickly and expects data by year-end.
Veru, a biopharmaceutical company specializing in innovative medicine for oncology and viral-induced acute respiratory distress syndrome, will see its CEO, Dr. Mitchell Steiner, present a keynote at Biomed Israel 2024. The event, taking place May 21-23 in Tel Aviv, Israel, focuses on life science and technology advancements. Dr. Steiner's presentation, scheduled for May 22, will discuss the effects of GLP-1 receptor agonists on muscle loss and weight management, particularly in older sarcopenic obese patients. The session aims to explore how preserving muscle mass can enhance the effectiveness of weight loss drugs.
Veru Inc. reported fiscal 2024 second quarter financial results and provided updates on its Enobosarm high-quality weight loss clinical program. The Phase 2b clinical study of enobosarm in combination with semaglutide is actively enrolling. The company has formed a high-quality weight loss Scientific Advisory Board with five medical experts and will present at upcoming medical conferences. Veru Inc. aims to develop innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU) will present at the GLP-1 Based Therapeutics Summit in Philadelphia, discussing Enobosarm, a drug to avoid muscle loss and enhance weight loss quality. The presentation aims to address muscle loss issues in weight management and the potential benefits of combining Enobosarm with a GLP-1 RA. The event is scheduled for May 15-16, 2024.
Veru Inc. (NASDAQ: VERU) will host a conference call and webcast on May 8, 2024, to discuss its fiscal 2024 second quarter financial results and provide a business update. The company focuses on developing innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU) has enrolled the first patients in a Phase 2b clinical trial of enobosarm and semaglutide combination for high-quality weight loss. The study aims to preserve muscle mass during weight loss therapy, with topline data expected in the fourth quarter of 2024.
Summary not available.